Literature DB >> 18684129

Recent role of splenectomy in chronic hepatic disorders.

Toru Ikegami1, Mitsuo Shimada, Satoru Imura.   

Abstract

For years splenectomy in hepatic disorders has been indicated only for the treatment of gastro-esophageal varices. However, with recent advances in medical and surgical treatments for chronic hepatic disorders, the use of splenectomy has been greatly expanded, such that splenectomy is used for reversing hypersplenism, for applying interferon treatment for hepatitis C, for treating hyperdynamic portal circulation associated with intractable ascites, and for controlling portal pressure during small grafts in living donor liver transplantation. Such experiences have shown the importance of portal hemodynamics, even in cirrhotic livers. Recent advances in surgical techniques have enabled surgeons to perform splenectomy more safely and less invasively, but the procedure still has considerable clinical outcomes. Splenectomy in hepatic disorders may become a more common procedure with expanded indications. However, it should also be noted that the long-term effects of splenectomy, in terms of improved hematological or hepatic function, is still not guaranteed. Moreover, the impact of splenectomy on immunologic status remains unclear and needs to be elucidated in both experimental and clinical settings.

Entities:  

Year:  2008        PMID: 18684129     DOI: 10.1111/j.1872-034X.2008.00384.x

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  17 in total

1.  Predictive factors for platelet count after laparoscopic splenectomy in cirrhotic patients.

Authors:  Daisuke Yoshida; Yoshihiro Nagao; Morimasa Tomikawa; Hirofumi Kawanaka; Tomohiko Akahoshi; Nao Kinjo; Hideo Uehara; Naotaka Hashimoto; Makoto Hashizume; Yoshihiko Maehara
Journal:  Hepatol Int       Date:  2011-09-30       Impact factor: 6.047

2.  Long-term postoperative outcomes of hypersplenism: laparoscopic versus open splenectomy secondary to liver cirrhosis.

Authors:  Jin Zhou; Zhong Wu; Prasoon Pankaj; Bing Peng
Journal:  Surg Endosc       Date:  2012-05-31       Impact factor: 4.584

3.  Hypersplenism is correlated with increased risk of hepatocellular carcinoma in patients with post-hepatitis cirrhosis.

Authors:  Xing Lv; Fan Yang; Xin Guo; Tao Yang; Ti Zhou; Xiaoping Dong; Yong Long; Dan Xiao; Yong Chen
Journal:  Tumour Biol       Date:  2016-01-11

4.  Prognostic effect of response to interferon therapy after laparoscopic splenectomy among patients with marked thrombocytopenia and hepatitis C virus-related cirrhosis.

Authors:  Hideyuki Tamai; Yoshiyuki Mori; Naoki Shingaki; Ryo Shimizu; Jyunya Nuta; Kosaku Moribata; Yoshimasa Maeda; Yosuke Muraki; Hisanobu Deguchi; Izumi Inoue; Takao Maekita; Mikitaka Iguchi; Jun Kato; Katsunari Takifuji; Hiroki Yamaue; Masao Ichinose
Journal:  Hepatol Int       Date:  2014-11-01       Impact factor: 6.047

5.  Impact of Splenic Volume and Splenectomy on Prognosis of Hepatocellular Carcinoma Within Milan Criteria After Curative Hepatectomy.

Authors:  Kazuki Takeishi; Hirofumi Kawanaka; Shinji Itoh; Norifumi Harimoto; Toru Ikegami; Tomoharu Yoshizumi; Ken Shirabe; Yoshihiko Maehara
Journal:  World J Surg       Date:  2018-04       Impact factor: 3.352

6.  Adverse factors responsible for below-normal platelet count after laparoscopic splenectomy and azygoportal disconnection.

Authors:  Dou-Sheng Bai; Wen-Yu Shao; Chi Zhang; Ping Chen; Sheng-Jie Jin; Guo-Qing Jiang
Journal:  Turk J Gastroenterol       Date:  2019-03       Impact factor: 1.852

7.  Prior splenic irradiation reduces hematologic adverse events during chemotherapy in pancreatic tail cancer: a report of a patient with liver cirrhosis.

Authors:  Kazuyoshi Ohkawa; Kazuhiro Katayama; Kenji Ikezawa; Tsukasa Kawaguchi; Chie Tamai; Kazuho Imanaka; Hiroyuki Uehara; Kunihito Gotoh; Hidenori Takahashi; Terumasa Yamada; Hiroaki Ohigashi; Kinji Nishiyama; Osamu Ishikawa
Journal:  Clin J Gastroenterol       Date:  2010-10-27

8.  Simultaneous microwave coagulo-necrotic therapy (MCN) and laparoscopic splenectomy for the treatment of hepatocellular carcinoma with cirrhotic hypersplenism.

Authors:  Tomoki Ryu; Yuko Takami; Norifumi Tsutsumi; Masaki Tateishi; Kazuhiro Mikagi; Yoshiyuki Wada; Hideki Saitsu
Journal:  Surg Today       Date:  2016-08-30       Impact factor: 2.549

9.  Very-Low-Dose Pegylated Interferon a2a Plus Ribavirin Therapy for Advanced Liver Cirrhosis Type C: A Possible Therapeutic Alternative without Splenic Intervention.

Authors:  Shogo Ohkoshi; Satoshi Yamagiwa; Masahiko Yano; Hiromichi Takahashi; Yo-Hei Aoki; Yasunobu Matsuda; Yutaka Aoyagi
Journal:  Case Rep Gastroenterol       Date:  2010-07-28

10.  Simultaneous hepatectomy and splenectomy versus hepatectomy alone for hepatocellular carcinoma complicated by hypersplenism: a meta-analysis.

Authors:  Wei Li; Shi-Qiang Shen; Shan-Min Wu; Zu-Bing Chen; Chao Hu; Rui-Chen Yan
Journal:  Onco Targets Ther       Date:  2015-08-19       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.